- Home
- AAL vs LEGN Comparison
AAL vs LEGN Comparison
Compare AAL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAL
- LEGN
- Stock Information
- Founded
- AAL 1930
- LEGN 2014
- Country
- AAL United States
- LEGN United States
- Employees
- AAL N/A
- LEGN N/A
- Industry
- AAL Air Freight/Delivery Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AAL Consumer Discretionary
- LEGN Health Care
- Exchange
- AAL Nasdaq
- LEGN Nasdaq
- Market Cap
- AAL 6.3B
- LEGN 7.0B
- IPO Year
- AAL N/A
- LEGN 2020
- Fundamental
- Price
- AAL $9.46
- LEGN $32.80
- Analyst Decision
- AAL Buy
- LEGN Strong Buy
- Analyst Count
- AAL 16
- LEGN 12
- Target Price
- AAL $14.74
- LEGN $79.00
- AVG Volume (30 Days)
- AAL 69.1M
- LEGN 1.6M
- Earning Date
- AAL 04-24-2025
- LEGN 05-12-2025
- Dividend Yield
- AAL N/A
- LEGN N/A
- EPS Growth
- AAL 3.11
- LEGN N/A
- EPS
- AAL 1.24
- LEGN N/A
- Revenue
- AAL $54,211,000,000.00
- LEGN $627,241,000.00
- Revenue This Year
- AAL $4.16
- LEGN $66.92
- Revenue Next Year
- AAL $5.58
- LEGN $51.77
- P/E Ratio
- AAL $7.61
- LEGN N/A
- Revenue Growth
- AAL 2.70
- LEGN 119.97
- 52 Week Low
- AAL $8.50
- LEGN $29.27
- 52 Week High
- AAL $19.10
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- AAL 38.88
- LEGN 45.92
- Support Level
- AAL $9.27
- LEGN $29.27
- Resistance Level
- AAL $11.23
- LEGN $35.11
- Average True Range (ATR)
- AAL 0.80
- LEGN 1.89
- MACD
- AAL 0.10
- LEGN 0.16
- Stochastic Oscillator
- AAL 35.16
- LEGN 60.48
About AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.